Thomas Frisell

7.0k total citations · 4 hit papers
133 papers, 4.4k citations indexed

About

Thomas Frisell is a scholar working on Rheumatology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Thomas Frisell has authored 133 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Rheumatology, 44 papers in Pathology and Forensic Medicine and 29 papers in Oncology. Recurrent topics in Thomas Frisell's work include Rheumatoid Arthritis Research and Therapies (59 papers), Multiple Sclerosis Research Studies (23 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Thomas Frisell is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (59 papers), Multiple Sclerosis Research Studies (23 papers) and Chronic Lymphocytic Leukemia Research (21 papers). Thomas Frisell collaborates with scholars based in Sweden, United States and United Kingdom. Thomas Frisell's co-authors include Johan Askling, Anna Sara Öberg, Arvid Sjölander, Niklas Långström, Paul Lichtenstein, Fredrik Piehl, Ralf Kuja‐Halkola, Jonatan Salzer, Anders Svenningsson and Peter Alping and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Neurology.

In The Last Decade

Thomas Frisell

124 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sibling Comparison Designs

2012 401 citations Thomas Frisell, Anna Sara Öberg et al. Epidemiology profile →
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

2019 346 citations Peter Alping, Joachim Burman et al. profile →
The Swedish medical birth register during five decades: documentation of the content and quality of the register

2023 149 citations Thomas Frisell et al. profile →
Diagnostic accuracy in the Swedish national patient register: a review including diagnoses in the outpatient register

2025 11 citations Thomas Frisell et al. profile →

Peers

Countries citing papers authored by Thomas Frisell

Since Specialization

Citations

This map shows the geographic impact of Thomas Frisell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Frisell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Frisell more than expected).

Fields of papers citing papers by Thomas Frisell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Frisell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Frisell. The network helps show where Thomas Frisell may publish in the future.

Co-authorship network of co-authors of Thomas Frisell

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Frisell. A scholar is included among the top collaborators of Thomas Frisell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Frisell. Thomas Frisell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab 2024 ·Annals of Neurology ·Fredrik Piehl, Peter Alping, (unknown), Simon Englund, Joachim Burman, Katharina Fink, Anna Fogdell‐Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer‐Gould, (unknown), Johan Mellergård, Petra Nilsson, Tomas Olsson, Jonatan Salzer, Anders Svenningsson, Thomas Frisell	3
2	Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study 2024 ·European Journal of Neurology ·(unknown), Björn Evertsson, (unknown), (unknown), Pierre de Flon, Yunzhang Wang, Jonatan Salzer, Jan Lycke, Katharina Fink, Thomas Frisell, Faiez Al Nimer, Anders Svenningsson	4
3	Real‐World Healthcare Cost Savings and Reduced Relapse Rate with Off‐Label Rituximab versus Disease‐Modifying Treatments Approved for Relapsing–Remitting Multiple Sclerosis: A Nationwide Cost‐Effectiveness Study 2024 ·Annals of Neurology ·Peter Alping, Martin Neovius, Fredrik Piehl, Thomas Frisell	1
4	Effectiveness of JAK Inhibitors Compared With Biologic Disease‐Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study 2024 ·Arthritis & Rheumatology ·(unknown), Daniela Di Giuseppe, Johan Askling, Stefan Bergman, Hannah Bower, Katerina Chatzidionysiou, Helena Forsblad‐d’Elia, Alf Kastbom, Tor Olofsson, Thomas Frisell, Carl Turesson	2
5	Glucocorticoid exposure and the risk of serious infections in rheumatoid arthritis: a marginal structural model application 2023 ·Lara D. Veeken ·(unknown), Arvid Sjölander, Bénédicte Delcoigne, Johan Askling, Thomas Frisell	8
6	Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis 2023 ·Lara D. Veeken ·(unknown), Saedís Saevarsdóttir, Lina-Marcela Díaz-Gallo, (unknown), Lars Alfredsson, Lars Klareskog, Eva Baecklund, Lena Björkman, Alf Kastbom, Solbritt Rantapää‐Dahlqvist, Carl Turesson, Ingileif Jónsdóttir, Kāri Stefánsson, Thomas Frisell, Leonid Padyukov, Johan Askling, Helga Westerlind	1
7	Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies 2023 ·Annals of the Rheumatic Diseases ·Teresa A. Simon, Lixian Dong, Samy Suissa, Kaleb Michaud, Sofia Pedro, Marc C. Hochberg, Maarten Boers, Johan Askling, Thomas Frisell, Anja Strangfeld, Yvette Meißner, Vadim Khaychuk, (unknown), Michael A. Maldonado	3
8	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology 2022 ·Annals of the Rheumatic Diseases ·Delphine S. Courvoisier, Kim Lauper, Joanna Kedra, Maarten de Wit, Bruno Fautrel, Thomas Frisell, Kimme L Hyrich, Florenzo Iannone, Pedro Machado, Lykke Midtbøll Ørnbjerg, Žiga Rotar, María José Santos, Tanja Stamm, Simon Stones, Anja Strangfeld, Sytske Anne Bergstra, Robert Landewé, Axel Finckh	12
9	Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration 2022 ·Lara D. Veeken ·Bénédicte Delcoigne, Sella Aarrestad Provan, Hilde Berner Hammer, Daniela Di Giuseppe, Thomas Frisell, Bente Glintborg, Gerður Gröndal, Björn Guðbjörnsson, Merete Lund Hetland, Brigitte Michelsen, Dan Nordström, Heikki Relas, Johan Askling	4
10	POS0637 SAFETY OF b/tsDMARDs FOR RA AS USED IN CLINICAL PRACTICE - RESULTS FROM THE LAST DECADE OF THE ARTIS PROGRAM 2022 ·Annals of the Rheumatic Diseases ·Thomas Frisell, Hannah Bower, Eva Baecklund, Daniela Di Giuseppe, Bénédicte Delcoigne, Nils Feltelius, (unknown), Elisabet Lindqvist, Ulf Lindström, Johan Askling	2
11	OP0267 A GENOME-WIDE INVESTIGATION OF PERSISTENCE TO TREATMENT WITH METHOTREXATE IN SWEDISH EARLY RHEUMATOID ARTHRITIS PATIENTS 2022 ·Annals of the Rheumatic Diseases ·(unknown), Saedís Saevarsdóttir, Lina-Marcela Díaz-Gallo, Lars Alfredsson, Lars Klareskog, Thomas Frisell, Leonid Padyukov, (unknown), (unknown)	1
12	OP0122 COMPARATIVE EFFECTIVENESS OF JAKI VERSUS BDMARDS; A NATIONWIDE STUDY IN RA 2021 ·Annals of the Rheumatic Diseases ·(unknown), Johan Askling, Katerina Chatzidionysiou, Helena Forsblad‐d’Elia, Alf Kastbom, Ulf Lindström, Carl Turesson, Thomas Frisell	2
13	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology 2021 ·RMD Open ·Kim Lauper, Joanna Kedra, Maarten de Wit, Bruno Fautrel, Thomas Frisell, Kimme L Hyrich, Florenzo Iannone, Pedro Machado, Lykke Midtbøll Ørnbjerg, Žiga Rotar, María José Santos, Tanja Stamm, Simon Stones, Anja Strangfeld, Robert Landewé, Axel Finckh, Sytske Anne Bergstra, Delphine S. Courvoisier	4
14	POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION 2021 ·Annals of the Rheumatic Diseases ·Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Alenius, Eva Baecklund, Katerina Chatzidionysiou, Nils Feltelius, Helena Forsblad‐d’Elia, Alf Kastbom, Lars Klareskog, Elisabet Lindqvist, Ulf Lindström, Carl Turesson, Christopher Sjöwall, Johan Askling	1
15	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers 2020 ·RMD Open ·Katerina Chatzidionysiou, Bénédicte Delcoigne, Thomas Frisell, Merete Lund Hetland, Bente Glintborg, Lene Dreyer, René Cordtz, Kristian Zobbe, Dan Nordström, Nina Trokovic, Kalle Aaltonen, Sella Aarrestad Provan, Gerður Gröndal, Björn Guðbjörnsson, Johan Askling	10
16	Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis 2019 ·European Journal of Neurology ·(unknown), (unknown), Markus Axelsson, Lenka Novakova, Thomas Frisell, Anders Svenningsson, Jan Lycke, Fredrik Piehl, Jonatan Salzer	26
17	Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology 2015 ·Multiple Sclerosis Journal ·Peter Alping, (unknown), Lenka Novakova, Jonatan Salzer, (unknown), Markus Axelsson, Clas Malmeström, Katharina Fink, Thomas Frisell, Jan Lycke, Anders Svenningsson, Fredrik Piehl	2
18	Maternal body mass index during early pregnancy, gestational weight gain, and risk of autism spectrum disorders: Results from a Swedish total population and discordant sibling study 2015 ·International Journal of Epidemiology ·Renee M. Gardner, Brian K. Lee, Cecilia Magnusson, Dheeraj Rai, Thomas Frisell, Håkan Karlsson, Selma Idring, Christina Dalman	99
19	Genetic contribution to postpartum haemorrhage in Swedish population: cohort study of 466 686 births 2014 ·BMJ ·Anna Sara Öberg, (unknown), Thomas Frisell, Michael F. Greene, C. Almqvist, Brian T. Bateman	16
20	Sibling Comparison Designs breakdown → 2012 ·Epidemiology ·Thomas Frisell, Anna Sara Öberg, Ralf Kuja‐Halkola, Arvid Sjölander	401

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact